Keros Therapeutics Inc. (KROS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?
Does Keros Therapeutics, Inc. (KROS) have what it takes to be a top stock pick for momentum investors? Let's find out.
KROS vs. ARGX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
KROS or NVZMY: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%
The consensus price target hints at a 34.2% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KROS vs. ARGX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?
The consensus price target hints at a 42.8% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to a loss of $1.41 per share a year ago.
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.25 per share a year ago.
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Exact Sciences (EXAS). But which of these two stocks is more attractive to value investors?
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates
Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $3.62 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $1.21 per share a year ago.
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
